Given the success of combination anti-PD-1 and anti-CTLA-4 ICB across diverse cancers, there is great interest in defining tumor-agnostic pretreatment biomarkers, including through using gut microbial abundance signatures. The gene discussed is CTLA4; the disease is cancer.